Novo Nordisk is a Danish multinational pharma company and the global leader in diabetes and obesity care. The company has been transformed by the GLP-1 revolution (Ozempic, Wegovy), making it Europe’s most valuable company.
Diabetes, Obesity, Rare Diseases
5-year financial trajectory
Business segment breakdown
Key product revenue comparison
Geographic revenue split
| Product | Indication | Revenue |
|---|---|---|
| Ozempic (semaglutide) | Type 2 Diabetes | $14.0B |
| Wegovy (semaglutide) | Obesity | $4.5B |
| Rybelsus (oral semaglutide) | Type 2 Diabetes | $1.5B |
| NovoRapid / NovoLog | Diabetes (insulin) | $4.0B |
| Tresiba (degludec) | Diabetes (insulin) | $2.0B |
| NovoSeven (recombinant FVIIa) | Hemophilia | $1.5B |
Novo Nordisk is the #8 pharma company and the undisputed leader in diabetes/obesity. GLP-1 franchise (Ozempic + Wegovy) has created the most dramatic growth story in pharma. Market cap exceeds $600B, making it Europe’s most valuable company.
Revenue projected to reach $45-50B by 2026 as manufacturing capacity expands. Cagrisema (next-gen obesity) could achieve 25%+ weight loss. MASH and Alzheimer’s indications could add $5B+ each. Primary risk is competition from Eli Lilly’s Mounjaro/Zepbound.
Novo Nordisk 2023 Annual Report. Revenue and financial data from SEC filings (Form 10-K/20-F). Pipeline data from company R&D presentations and ClinicalTrials.gov. Market analysis by Medifirm Intelledge Global.